Cork, M.J. orcid.org/0000-0003-4428-2428, McMichael, A., Teng, J. et al. (6 more authors) (2022) Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis : an analysis of patient‐reported outcomes. Journal of the European Academy of Dermatology and Venereology, 36 (3). pp. 422-433. ISSN 0926-9959
Abstract
Background
A significant improvement in clinical signs was demonstrated with abrocitinib relative to placebo in adolescents with moderate-to-severe atopic dermatitis (AD) in three phase 3, randomized, double-blinded, placebo-controlled studies (JADE TEEN [ClinicalTrials.gov, NCT03796676], JADE MONO-1 [NCT03349060] and JADE MONO-2 [NCT03575871]).
Objectives
To evaluate the impact of abrocitinib on patient-reported signs/symptoms, including sleep loss and quality of life among adolescents with moderate-to-severe AD.
Methods
JADE TEEN, JADE MONO-1 and JADE MONO-2 were conducted in the Asia–Pacific region, Europe and North America and included patients aged 12 to 17 years with moderate-to-severe AD and inadequate response to ≥4 consecutive weeks of topical medication or treatment with systemic therapy for AD. Patients were randomly assigned (1:1:1, JADE TEEN; 2:2:1, JADE MONO-1/-2) to receive once-daily oral abrocitinib (200 mg or 100 mg) or placebo for 12 weeks in combination with topical therapy (JADE TEEN) or as monotherapy (JADE MONO-1/-2). Data from adolescent patients in JADE MONO-1/-2 were pooled for these analyses.
Results
At week 12, more adolescents treated with abrocitinib (200 mg or 100 mg) vs. placebo achieved a ≥4-point improvement from baseline in the Patient-Oriented Eczema Measure in JADE TEEN (83.9% and 77.0% vs. 60.2%) and JADE MONO-1/-2 (83.0% and 69.4% vs. 43.5%) and a ≥6-point improvement from baseline in the Children’s Dermatology Life Quality Index in JADE TEEN (73.8% and 67.5% vs. 56.5%) and JADE MONO-1/-2 (70.0% and 57.1% vs. 19.0%). Significant improvements in SCORing Atopic Dermatitis Visual Analog Scale for sleep loss scores were demonstrated with abrocitinib vs. placebo at weeks 2 to 12 in JADE TEEN and JADE MONO-1/-2.
Conclusions
Patient-reported signs/symptoms, including reduction of sleep loss and quality of life, were substantially improved with abrocitinib monotherapy or combination therapy relative to placebo in adolescents with moderate-to-severe AD.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2021 Pfizer Inc. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes (http://creativecommons.org/licenses/by-nc/4.0/). |
Keywords: | abrocitinib; adolescents; atopic dermatitis; patient-reported outcomes |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 15 Nov 2021 10:56 |
Last Modified: | 16 Mar 2022 11:43 |
Status: | Published |
Publisher: | Wiley |
Refereed: | Yes |
Identification Number: | 10.1111/jdv.17792 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:180438 |